Oslo, Norway, August 20, 2026 - Lytix Biopharma ASA ("Lytix" or the "Company") will release its second quarter 2026 financial results on Thursday, August 27th, 2026.
Join us for a live webcast presentation featuring CEO Øystein Rekdal, CFO Gjest Breistein, CBO Timothy Herpin, and CMO Karim Benhadji where they will present the quarterly update and provide key insights.
Date: Thursday, August 27th, 2026
Time: 14:00 CET
Q&A Session:
We welcome your questions in advance. Please send them to post@lytixbiopharma.com, and they will be addressed during the Q&A session following the presentation.
Webcast Details:
The presentation and Q&A session will be conducted in English. You can view the live event by registering here: https://qcnl.tv/p/wFBmNeuCBCK8I_UvrCJ8Dg
Missed the Live Session?
A recording of the presentation will be available shortly after the event on our financial reports page: https://www.lytixbiopharma.com/investors/reports-and-presentations/financial-reports
For more information, please contact:
Gjest Breistein, CFO
+47 952 60 512
gjest.breistein@lytixbiopharma.com
About Lytix
Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with a highly differentiated oncolytic molecule platform based on world-leading research in host-defense peptide-derived molecules. Lytix Biopharma's lead product, ruxotemitide (formerly LTX-315), is a first-in-class oncolytic molecule representing a new approach to maintaining durable anti-cancer immunity. Lytix Biopharma has a pipeline of molecules that work across multiple cancer indications and treatment settings, both as mono- and combination therapy. Lytix is listed on Euronext Growth Oslo under the ticker LYTIX. For more information, visit www.lytixbiopharma.com.